# Lipoic Acid and Omega-3 Fatty Acids for Cognitive Impairment in Multiple Sclerosis

> **NCT02133664** · PHASE1,PHASE2 · COMPLETED · sponsor: **Oregon Health and Science University** · enrollment: 54 (actual)

## Conditions studied

- Multiple Sclerosis
- Cognition

## Interventions

- **DRUG:** lipoic acid and omega-3 fatty acids
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02133664
- **Lead sponsor:** Oregon Health and Science University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-06
- **Primary completion:** 2016-05
- **Final completion:** 2016-05
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2017-06-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02133664

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02133664, "Lipoic Acid and Omega-3 Fatty Acids for Cognitive Impairment in Multiple Sclerosis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02133664. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*